NCHR Comments on HHS Draft Strategic Plan FY2018-2022

October 26, 2017. The HHS has drafted a strategic plan for implementation over the next several years. We object to language that is non-scientific and themes which weight political rhetoric and ideology over sound scientific principles. Read more of our comments here.

Read More »

NCHR Letter to the DC City Council on Artificial Turf

October 26, 2017. It is clear that city officials have assumed artificial turf products are safe because the salespeople told them they were safe. Unfortunately, there is clear scientific evidence that these materials are potentially harmful, and the only question is how harmful are they and how much exposure is likely to be harmful? Our children deserve better. 

Read More »

NCHR Testimony at the FDA Panel on Ataluren

September 28, 2017. We agree with FDA scientists that the data today do not indicate significant benefit in randomized, double-blind, placebo-controlled trials, such as Study 7. Only after making many post-hoc changes did ataluren show it was effective for ADP patients, but this was not replicated in Study 20. As you know, those post-hoc manipulations do not provide clear evidence of efficacy. For both studies, 90% and 79% of patients were White. But the CDC reports that Hispanic males are disproportionately likely to have these conditions. It is essential that an adequate number of Hispanic males be analyzed to determine if they can benefit from a treatment such as ataluren.

Read More »